Stock performance snapshot and recent context

FIGS (FIGS) has drawn investor attention after a mixed stretch, with the stock up about 6.1% in the latest session but down roughly 15.8% over the past week and month.

That sharp 1 day share price gain sits alongside a weaker recent patch, with the 7 day and 30 day share price returns both down around 16%, even as the 90 day share price return is up about 20% and the 1 year total shareholder return is very large. This suggests momentum has cooled in the short term after a strong longer run.

If you are comparing FIGS with other healthcare focused opportunities, this is a good moment to see what else fits your criteria through 33 healthcare AI stocks

So, with FIGS posting mixed short term returns, positive annual revenue and net income growth, and trading below the average analyst price target, is the stock a misunderstood value, or is the market already pricing in future growth?

Most Popular Narrative: 69.3% Overvalued

Julio's widely followed narrative puts FIGS' fair value at $7.21, well below the last close at $12.21, which points to a rich valuation relative to that framework.

The company, on an absolute basis, is still growing well. Further, it has several growth levers, such as expanding its product range, entering new markets, and leaning into its “TEAMS” offering.

Curious what kind of revenue trajectory and profit margins are baked into that fair value, and how much credit this narrative gives to TEAMS and international expansion.

Result: Fair Value of $7.21 (OVERVALUED)

However, that story could shift if execution slips again or if economic pressure hits demand for FIGS' premium-priced gear among healthcare professionals.

Next Steps

Given the mix of concern and optimism running through this story, it makes sense to review the data for yourself, weigh both sides, and see the 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If FIGS has your attention, do not stop here. Widen your search so you can compare this opportunity with other stocks that fit the kind of portfolio you want.

• Spot potential high growth stories early by reviewing 28 elite penny stocks with strong financials, which pair smaller market caps with stronger financial markers than typical micro caps.
• Zero in on stocks that combine quality fundamentals with appealing pricing using the 46 high quality undervalued stocks to see which companies line up with your return expectations.
• Prioritise sleep at night holdings by filtering for companies in the 68 resilient stocks with low risk scores that score better on balance sheet strength and volatility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.